UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of innate and adaptive immunity to RSV in young children

Cellular immunology, 2024-05, Vol.399-400, p.104824, Article 104824

2024

Volltextzugriff (PDF)

The race to make vaccines for a dangerous respiratory virus

Nature (London), 2021-12, Vol.600 (7889), p.379-380

Powell, Kendall

2021

Volltextzugriff (PDF)

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

The Lancet infectious diseases, 2016-08, Vol.16 (8), p.e153-e163

2016

Volltextzugriff (PDF)

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

The Journal of infectious diseases, 2024-10, Vol.230 (4), p.e905-e916

2024

Volltextzugriff (PDF)

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

The Journal of infectious diseases, 2024-07, Vol.230 (1), p.e102-e110

2024

Volltextzugriff (PDF)

Passive and active immunization against respiratory syncytial virus for the young and old

Expert review of vaccines, 2017-07, Vol.16 (7), p.737-749

2017

Volltextzugriff (PDF)

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Clinical infectious diseases, 2024-10, Vol.79 (4), p.1088-1098

2024

Volltextzugriff (PDF)

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

Clinical infectious diseases, 2024-08, Vol.79 (4), p.1074-1084

2024

Volltextzugriff (PDF)

Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses

Journal of virology, 2015-09, Vol.89 (17), p.8974-8981

2015

Volltextzugriff (PDF)

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

The Journal of infection, 2024-08, Vol.89 (2), p.106211, Article 106211

2024

Volltextzugriff (PDF)

Lung ILC2s are activated in BALB/c mice born to immunized mothers despite complete protection against respiratory syncytial virus

Frontiers in immunology, 2024-05, Vol.15, p.1374818-1374818

2024

Volltextzugriff (PDF)

A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus

Virology (New York, N.Y.), 2019-08, Vol.534, p.1-13

2019

Volltextzugriff (PDF)

Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy

Neonatology (Basel, Switzerland), 2024, Vol.121 (3), p.271-282

2024

Volltextzugriff (PDF)

Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model

Scientific reports, 2017-02, Vol.7 (1), p.42428-42428, Article 42428

2017

Volltextzugriff (PDF)

Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus

American journal of respiratory and critical care medicine, 2015-05, Vol.191 (9), p.1040-1049

2015

Volltextzugriff (PDF)

Antibody-mediated protection against respiratory syncytial virus in children

European respiratory review, 2024-10, Vol.33 (174), p.240106

2024

Volltextzugriff (PDF)

A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease

The Journal of immunology (1950), 2016-02, Vol.196 (4), p.1721-1731

2016

Volltextzugriff (PDF)

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice

Frontiers in immunology, 2024-10, Vol.15, p.1451433

2024

Volltextzugriff (PDF)

Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge

Journal of virology, 2017-10, Vol.91 (19)

2017

Volltextzugriff (PDF)

Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection

Frontiers in immunology, 2020-07, Vol.11, p.1673-1673

2020

Volltextzugriff (PDF)

A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus

Virology (New York, N.Y.), 2016-12, Vol.499, p.288-297

2016

Volltextzugriff (PDF)

The MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes

Revista argentina de microbiología, 2024-04, Vol.56 (2), p.125-133

2024

Volltextzugriff (PDF)

Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients

Transplantation, 2020-06, Vol.104 (6), p.1280-1286

2020

Volltextzugriff (PDF)

Respiratory syncytial virus infection provides protection against severe acute respiratory syndrome coronavirus challenge

Journal of virology, 2024-09, Vol.98 (9), p.e0066924

2024

Volltextzugriff (PDF)

The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia

The Journal of immunology (1950), 2008-12, Vol.181 (11), p.7958-7968

2008

Volltextzugriff (PDF)

1 – 25 von 881

Suche als RSS-Feed

Aktive Filter

ThemaRespiratory Syncytial Virus

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(790)
Mit Volltextzugriff
(602)

Publikationsform

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(728)
Life Sciences & Biomedicine
(720)
Humans
(658)
Male
(544)
Immunology
(369)
Infant
(364)
Animals
(336)
Respiratory Syncytial Viruses - Immunology
(306)
Respiratory Syncytial Virus Infections - Immunology
(300)
Infectious Diseases
(273)
Biological And Medical Sciences
(249)
Child, Preschool
(242)
Infant, Newborn
(197)
Medical Sciences
(192)
Mice
(191)
Microbiology
(180)
Mice, Inbred Balb C
(173)
Child
(166)
Pediatrics
(164)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Development of innate and adaptive immunity to RSV in young children

The race to make vaccines for a dangerous respiratory virus

Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality?

Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination

Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial

Passive and active immunization against respiratory syncytial virus for the young and old

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age

Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines in adults

Lung ILC2s are activated in BALB/c mice born to immunized mothers despite complete protection against respiratory syncytial virus

A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus

Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy

Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model

Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus

Antibody-mediated protection against respiratory syncytial virus in children

A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice

Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge

Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection

A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus

The MVA vector expressing the F protein of bovine respiratory syncytial virus is immunogenic in systemic and mucosal immunization routes

Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients

Respiratory syncytial virus infection provides protection against severe acute respiratory syndrome coronavirus challenge

The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia

Aktive Filter

Suchergebnisse filtern